Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Buy” by Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has received an average rating of “Buy” from the nineteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $129.38.

ARVN has been the subject of a number of research reports. Roth Capital raised their price objective on Arvinas from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Monday, August 9th. SVB Leerink initiated coverage on Arvinas in a research report on Thursday, October 14th. They issued an “outperform” rating and a $115.00 price objective for the company. Zacks Investment Research downgraded Arvinas from a “buy” rating to a “hold” rating in a research report on Tuesday, October 12th. Stifel Nicolaus initiated coverage on Arvinas in a research report on Wednesday, September 29th. They issued a “buy” rating and a $115.00 price objective for the company. Finally, Oppenheimer upgraded Arvinas from a “market perform” rating to an “outperform” rating in a research report on Thursday, November 4th.

In related news, insider Ian Taylor sold 20,000 shares of the firm’s stock in a transaction on Monday, November 15th. The stock was sold at an average price of $84.04, for a total transaction of $1,680,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy M. Shannon sold 36,411 shares of Arvinas stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $89.09, for a total value of $3,243,855.99. The disclosure for this sale can be found here. Over the last three months, insiders sold 276,899 shares of company stock valued at $24,752,298. 6.45% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of the company. Credit Suisse AG boosted its position in shares of Arvinas by 0.6% in the 3rd quarter. Credit Suisse AG now owns 30,888 shares of the company’s stock worth $2,538,000 after purchasing an additional 193 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Arvinas by 0.4% in the 3rd quarter. Alliancebernstein L.P. now owns 55,000 shares of the company’s stock worth $4,520,000 after purchasing an additional 200 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of Arvinas by 1.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 17,452 shares of the company’s stock worth $1,434,000 after purchasing an additional 210 shares during the last quarter. Advisor Group Holdings Inc. boosted its position in shares of Arvinas by 142.7% in the 3rd quarter. Advisor Group Holdings Inc. now owns 415 shares of the company’s stock worth $34,000 after purchasing an additional 244 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Arvinas by 3.5% in the 2nd quarter. AQR Capital Management LLC now owns 8,538 shares of the company’s stock worth $657,000 after purchasing an additional 291 shares during the last quarter. Institutional investors and hedge funds own 99.83% of the company’s stock.

NASDAQ:ARVN traded down $2.02 during mid-day trading on Friday, hitting $74.44. 1,661,135 shares of the company’s stock traded hands, compared to its average volume of 376,327. The firm has a 50 day moving average of $83.96 and a two-hundred day moving average of $83.80. Arvinas has a 12 month low of $25.00 and a 12 month high of $108.46. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of -19.59 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Wednesday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of $2.13 by ($3.07). Arvinas had a negative net margin of 794.97% and a negative return on equity of 27.02%. The business had revenue of $9.28 million for the quarter, compared to the consensus estimate of $26.89 million. During the same quarter in the previous year, the company earned ($0.79) EPS. Arvinas’s revenue for the quarter was up 22.2% compared to the same quarter last year. On average, equities analysts forecast that Arvinas will post -3.55 earnings per share for the current year.

About Arvinas

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

Further Reading: Black Swan

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.